Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma

British Journal of Haematology

Volumn 166, Issue 1, 2014, Pages 77-83

  Feldman, Tatyana ^a   Mato, Anthony R ^a   Chow, Kar F ^a   Protomastro, Ewelina A ^a   Yannotti, Kara M L ^a   Bhattacharyya, Pritish ^a   Yang, Xiao ^a   Donato, Michele L ^a   Rowley, Scott D ^a   Carini, Carolanne ^a   Valentinetti, Marisa ^a   Smith, Judith ^a   Gadaleta, Gabriella ^a   Bejot, Coleen ^a   Stives, Susan ^a   Timberg, Mary ^a   Kdiry, Sabrina ^a   Pecora, Andrew L ^a   Beaven, Anne W ^b   Goy, Andre ^a  

^a HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bone marrow transplantation; Diffuse large B cell lymphoma; Lenalidomide; Rituximab; Salvage

Indexed keywords

CARBOPLATIN; CARMUSTINE; CYTARABINE; ETOPOSIDE; IFOSFAMIDE; LENALIDOMIDE; MELPHALAN; RITUXIMAB;

ADULT; AGED; ANEMIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER RECURRENCE; CHEMOSENSITIVITY; CLINICAL ARTICLE; CONSOLIDATION CHEMOTHERAPY; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FATIGUE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPENIA; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIMARY TUMOR; PRIORITY JOURNAL; RASH; SALVAGE THERAPY; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE;

BONE MARROW TRANSPLANTATION; DIFFUSE LARGE B-CELL LYMPHOMA; LENALIDOMIDE; RITUXIMAB; SALVAGE;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; CARBOPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ETOPOSIDE; FEMALE; HUMANS; IFOSFAMIDE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RECURRENCE; SALVAGE THERAPY; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84902316289     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12846     Document Type: Article

References (23)

1. Campo, E., Swerdlow, S.H., Harris, N.L., Pileri, S., Stein, H. & Jaffe, E.S. (2011) The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood, 117, 5019-5032.
2. Cheson, B.D., Pfistner, B., Juweid, M.E., Gascoyne, R.D., Specht, L., Horning, S.J., Coiffier, B., Fisher, R.I., Hagenbeek, A., Zucca, E., Rosen, S.T., Stroobants, S., Lister, T.A., Hoppe, R.T., Dreyling, M., Tobinai, K., Vose, J.M., Connors, J.M., Federico, M. & Diehl, V.; International Harmonization Project on Lymphoma. (2007) Revised response criteria for malignant lymphoma. Journal of Clinical Oncology, 25, 579-586.
3. Chiappella, A., Tucci, A., Castellino, A., Pavone, V., Baldi, I., Carella, A.M., Orsucci, L., Zanni, M., Salvi, F., Liberati, A.M., Gaidano, G., Bottelli, C., Rossini, B., Perticone, S., De Masi, P., Ladetto, M., Ciccone, G., Palumbo, A., Rossi, G. & Vitolo, U.; Fondazione Italiana Linfomi. (2013) Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi. Haematologica, 98, 1732-1738.
4. Eve, H.E., Carey, S., Richardson, S.J., Heise, C.C., Mamidipudi, V., Shi, T., Radford, J.A., Auer, R.L., Bullard, S.H. & Rule, S.A. (2012) Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences. British Journal of Haematology, 159, 154-163.
5. Gisselbrecht, C. (2012) Is there any role for transplantation in the rituximab era for diffuse large B-cell lymphoma? Hematology American Society of Hematology Education Program, 2012, 410-416.
6. Gisselbrecht, C., Glass, B., Mounier, N., Singh Gill, D., Linch, D.C., Trneny, M., Bosly, A., Ketterer, N., Shpilberg, O., Hagberg, H., Ma, D., Brière, J., Moskowitz, C.H. & Schmitz, N. (2010) Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. Journal of Clinical Oncology, 28, 4184-4190.
7. Green, T.M., Young, K.H., Visco, C., Xu-Monette, Z.Y., Orazi, A., Go, R.S., Nielsen, O., Gadeberg, O.V., Mourits-Andersen, T., Frederiksen, M., Pedersen, L.M. & Møller, M.B. (2012) Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. Journal of Clinical Oncology, 30, 3460-3467.
8. Hans, C.P., Weisenburger, D.D., Greiner, T.C., Gascoyne, R.D., Delabie, J., Ott, G., Müller-Hermelink, H.K., Campo, E., Braziel, R.M., Jaffe, E.S., Pan, Z., Farinha, P., Smith, L.M., Falini, B., Banham, A.H., Rosenwald, A., Staudt, L.M., Connors, J.M., Armitage, J.O. & Chan, W.C. (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood, 103, 275-282.
9. Hernandez-Ilizaliturri, F.J., Deeb, G., Zinzani, P.L., Pileri, S.A., Malik, F., Macon, W.R., Goy, A., Witzig, T.E. & Czuczman, M.S. (2011) Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer, 117, 5058-5066.
10. Hitz, F., Fischer, N., Pabst, T., Caspar, C., Berthod, G., Eckhardt, K., Berardi Vilei, S., Zucca, E. & Mey, U.; Swiss Group for Clinical Cancer Research (SAKK). (2013) Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38/08 trial. Annals of Hematology, 92, 1033-1040.
11. Kewalramani, T., Zelenetz, A.D., Nimer, S.D., Portlock, C., Straus, D., Noy, A., O'Connor, O., Filippa, D.A., Teruya-Feldstein, J., Gencarelli, A., Qin, J., Waxman, A., Yahalom, J. & Moskowitz, C.H. (2004) Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood, 103, 3684-3688.
12. Kobayashi, T., Tsutsumi, Y., Sakamoto, N., Nagoshi, H., Yamamoto-Sugitani, M., Shimura, Y., Mizutani, S., Matsumoto, Y., Nishida, K., Horiike, S., Asano, N., Nakamura, S., Kuroda, J. & Taniwaki, M. (2012) Double-hit lymphomas constitute a highly aggressive subgroup in diffuse large B-cell lymphomas in the era of rituximab. Japanese Journal of Clinical Oncology, 42, 1035-1042.
13. Mey, U.J., Olivieri, A., Orlopp, K.S., Rabe, C., Strehl, J.W., Gorschlueter, M., Hensel, M., Flieger, D., Glasmacher, A.G. & Schmidt-Wolf, I.G. (2006) DHAP in combination with rituximab vs DHAP alone as salvage treatment for patients with relapsed or refractory diffuse large B-cell lymphoma: a matched-pair analysis. Leukaemia & Lymphoma, 47, 2558-2566.
14. Mounier, N., Canals, C., Gisselbrecht, C., Cornelissen, J., Foa, R., Conde, E., Maertens, J., Attal, M., Rambaldi, A., Crawley, C., Luan, J.J., Brune, M., Wittnebel, S., Cook, G., van Imhoff, G.W., Pfreundschuh, M. & Sureda, A.; Lymphoma Working Party of European Blood and Marrow Transplantation Registry (EBMT). (2012) High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry. Biology of Blood and Marrow Transplantation, 18, 788-793.
15. ®) Non-Hodgkin's Lymphomas. Version 2.2013. Available at http://www.nccn.org/. Accessed November 2013.
16. Nogai, H., Dorken, B. & Lenz, G. (2011) Pathogenesis of non-Hodgkin's lymphoma. Journal of Clinical Oncology, 29, 1803-1811.
17. Nowakowski, G.S., LaPlant, B., Habermann, T.M., Rivera, C.E., Macon, W.R., Inwards, D.J., Micallef, I.N., Johnston, P.B., Porrata, L.F., Ansell, S.M., Klebig, R.R., Reeder, C.B. & Witzig, T.E. (2011) Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study. Leukemia, 25, 1877-1881.
18. Wang, M., Fayad, L., Wagner-Bartak, N., Zhang, L., Hagemeister, F., Neelapu, S.S., Samaniego, F., McLaughlin, P., Fanale, M., Younes, A., Cabanillas, F., Fowler, N., Newberry, K.J., Sun, L., Young, K.H., Champlin, R., Kwak, L., Feng, L., Badillo, M., Bejarano, M., Hartig, K., Chen, W., Chen, Y., Byrne, C., Bell, N., Zeldis, J. & Romaguera, J. (2012) Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncology, 13, 716-723.
19. Witzig, T.E., Vose, J.M., Zinzani, P.L., Reeder, C.B., Buckstein, R., Polikoff, J.A., Bouabdallah, R., Haioun, C., Tilly, H., Guo, P., Pietronigro, D., Ervin-Haynes, A.L. & Czuczman, M.S. (2011) An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Annals of Oncology, 22, 1622-1627.
20. Wu, L., Adams, M., Carter, T., Chen, R., Muller, G., Stirling, D., Schafer, P. & Bartlett, J.B. (2008) Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20 + tumor cells. Clinical Cancer Research, 14, 4650-4657.
21. Zaja, F., De Luca, S., Vitolo, U., Orsucci, L., Levis, A., Salvi, F., Rusconi, C., Ravelli, E., Tucci, A., Bottelli, C., Balzarotti, M., Brusamolino, E., Bonfichi, M., Pileri, S.A., Sabattini, E., Volpetti, S., Monagheddu, C., Vacca, A., Ria, R. & Fanin, R. (2012) Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers. Haematologica, 97, 416-422.
22. Zhang, L., Qian, Z., Cai, Z., Sun, L., Wang, H., Bartlett, J.B., Yi, Q. & Wang, M. (2009) Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. American Journal of Hematology, 84, 553-559.
23. Zinzani, P.L., Pellegrini, C., Gandolfi, L., Stefoni, V., Quirini, F., Derenzini, E., Broccoli, A., Argnani, L., Pileri, S. & Baccarani, M. (2011) Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. Clinical Lymphoma Myeloma & Leukemia, 11, 462-466.